<?xml version="1.0" encoding="UTF-8"?>
<p id="p0180">Favilavir is a guanine analog with the broad-spectrum antiviral activities through its selective inhibition of viral RNA-dependent RNA polymerase [
 <xref rid="bb0650" ref-type="bibr">130</xref>]. Favilavir has efficacy against various RNA viruses, including influenza, ebola, yellow fever, chikungunya, norovirus, and enterovirus [
 <xref rid="bb0655" ref-type="bibr">131</xref>,
 <xref rid="bb0660" ref-type="bibr">132</xref>]. A recent cell line study suggested its efficacy against the SARS-CoV-II [
 <xref rid="bb0665" ref-type="bibr">133</xref>]. While it got the approval for novel influenza treatment, favipiravir is currently on the clinical trials for COVID-19 treatment by the National Infectious Diseases Scientific Science Research Center and the Shenzhen Third People's Hospital [
 <xref rid="bb0670" ref-type="bibr">134</xref>]. The preliminary results in eighty patients reported the superior efficacy of favipiravir than the lopinavir/ritonavir combination without the significant adverse reactions [
 <xref rid="bb0675" ref-type="bibr">135</xref>,
 <xref rid="bb0680" ref-type="bibr">136</xref>].
</p>
